As Terumo Neuro, the company is poised to continue its legacy of innovation with an enhanced focus on driving impactful growth and leveraging Terumo’s global resources and reputation.

Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 ...

"Terumo Neuro's SOFIA 88 Neurovascular Support Catheter is truly one of the best products in this category, especially when using a short 8F sheath," said Dr. Ameer Hassan, Head of Neuroscience ...

As Terumo Neuro, the company is poised to continue its legacy of innovation with an enhanced focus on driving impactful growth and leveraging Terumo’s global resources and reputation.

More than 25,000 Devices Implanted Worldwide from 2010-20251 ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned ...

Terumo Neuro Also Features Much-Anticipated SOFIA™ 88 Neurovascular Support Catheter Showcased at ISC Symposium led by Dr. Ameer E. Hassan on Thursday, February 6 th ALISO VIEJO, Calif. and LOS ...

Data on file, Terumo Neuro. Pierot L, Moret J, Barreau X, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series.

The video released from Terumo Neuro and Tulane University School of Medicine featuring Dr. Kendrick Johnson will be available for viewing on terumoneuro.com and medicine.tulane.edu, as well as ...

News provided by Terumo Neuro May 13, 2025, 9:00 AM ET Terumo Neuro's SOFIA ™ Catheter Line is Backed By 10 Years of Proven Clinical Performance and Innovation – The New SOFIA™ 88 Catheter ...

Terumo Neuro's SOFIA Catheter Line is Backed By 10 Years of Proven Clinical Performance1-9 and Innovation - The New SOFIA Flow 88 Offers Reliable Trackability, Proximal Stability and Vessel-Friendly ...